is, the nasal cavity, paranasal sinuses, parotid gland, cervical sympathetic chain, pharynx, larynx, trachea, aortic arch, ciliary ganglion
| MATERIAL S AND ME THODS

| RE SULTS
| Clinical characteristics
One hundred and forty-seven patients, 47 male (32%) and 100 female (68%), with a total of 289 HNPGLs were diagnosed in a 60-year period.
Sixty-three patients (43%) presented with a positive family history, while the remaining 84 patients (57%) had no known family history of and these tumours were confirmed to be PGL by histopathology.
Multiple synchronous or metachronous HNPGLs were found in 79 of 147 patients (54%), up to a maximum of six metachronous HNPGL.
At diagnosis, 29 out of 96 (30%) biochemically screened HNPGL patients showed excessive catecholamine secretion. In 25 out of 29 (86%) of these patients, additional imaging was performed in order to identify the source of catecholamine excess. Two of these patients (2/29; 7%) were diagnosed with a concurrent PHEO, one of these patients was diagnosed with metastatic disease (1/29; 3%), and 2 (2/29; 7%) patients were diagnosed with a sPGL.
This percentage was 6/10 (60%) for SDHB patients and 16/52 (31%) for SDHD HNPGL patients. In three of four patients (75%) with a concurrent PHEO, excessive catecholamine secretion was present.
DNA tests were performed in 98/147 (67%) of HNPGL patients.
Patient characteristics categorised per genetic subgroup are outlined in Table 1 .
Sixty-four of 98 patients who had their DNA tested (65%) carried a pathogenic variant in SDHD, of whom 50 of 64 (78%) had a
Key Points
• Paragangliomas of the head and neck (HNPGLs) are rare, slow-growing and usually benign tumours that arise in the paraganglion tissue associated with the autonomic nervous system.
• Management strategies and outcome of 147 patients with a total of 289 HNPGLs in a 60-year period were evaluated.
• In HNPGLs patients, the clinician should be aware of variable clinical manifestations, such as the risk of multifocality, associated sympathetic PGL, concurrent pheochromocytoma, catecholamine excess and risk of metastatic disease.
• A decreasing number of HNPGLs were surgically resected. Increasingly, an active surveillance strategy has become the treatment of choice.
• Table 2 . Treatment strategies and outcome for patients with a solitary HNPGL are outlined in Table 3 . As different treatment strategies may apply different tumour locations within one patient, a single treatment strategy could not be associated with a patient with multiple HNPGLs.
| Management
Since 1956, an increasing number of HNPGLs have been diagnosed 
| D ISCUSS I ON
This single-centre study describes clinical characteristics and outcome of treatment in a population HNPGL patients. In accordance with earlier reports, the vast majority of HNPGLs is located at the bifurcation of the carotid artery (59%), the jugular foramen (43%), 
